
ABL Bio’s partner to unveil ABL111 combo therapy’s phase 1 results in Europe
ABL Bio said Tuesday that its partner I-Mab will present data from the phase 1b study of ABL111 (trademark name: Givastomig) combination therapy in a mini oral presentation at the European Society for Medical Oncology Gastrointestinal Cancers Congress ( …